Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
Immunovant, Inc. Chief Executive Officer Eric Venker received new equity awards as compensation. He was granted stock options covering 336,043 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036.
He also received 232,252 restricted stock units, each representing one share of common stock upon vesting. The options and RSUs vest 25% on April 1, 2027, with the remaining amounts vesting in regular installments thereafter, contingent on his continuous service. Following the RSU grant, he directly holds 251,813 shares of common stock.
Immunovant, Inc. Chief Financial Officer Tiago Girao received new equity awards as part of his compensation. He was granted stock options for 94,002 shares of common stock at an exercise price of $24.61 per share, expiring in 2036, and 64,968 restricted stock units that convert into common shares as they vest.
The RSUs vest 25% on April 1, 2027, with the remainder in 12 quarterly installments, while the options vest 25% on April 1, 2027 and the balance in 36 monthly installments, all contingent on continued service. Following the grant, he holds 273,356 common shares directly.
Immunovant, Inc. Chief Executive Officer Eric Venker reported the vesting and settlement of capped value appreciation rights (CVARs) into 368,750 shares of common stock on April 1, 2026, based on a hurdle price of $14.46 per share. A total of 334,960 shares were then disposed of to the issuer at $25.10 per share, with the remaining shares forming his updated equity position.
On April 2, 2026, Venker sold 12,820 shares at a weighted average price of $24.04 and 1,409 shares at a weighted average price of $24.60. Footnotes state these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations tied to the CVAR settlement and did not represent discretionary trading. Following these transactions, Venker directly holds 19,561 shares of Immunovant common stock.
Immunovant, Inc.’s Chief Legal Officer Christopher Van Tuyl reported a mandated tax-related share sale. On March 18, he disposed of 2,877 shares of common stock at $24.97 per share to cover tax withholding obligations from recently vested restricted stock units. After this transaction, he directly holds 147,053 shares. The company notes this "sell to cover" sale was required under its tax withholding policy and was not a discretionary trade.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported three open-market sales of common stock that together totaled 3,238 shares on February 25, 2026. The reported transactions were executed at weighted average prices of $26.98, $28.16, and $28.90 per share.
According to the footnotes, these shares were sold to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units that vested on February 18, 2026. The filing states that the sales were mandated under a “sell to cover” arrangement and do not represent discretionary trading decisions by the officer.
A holder of IMVT common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 5,800 common shares through Morgan Stanley Smith Barney LLC, with an approximate sale date of February 10, 2026 on the NASDAQ.
The shares to be sold were acquired as restricted stock from the issuer in January 2026 in two grants of 3,770 and 2,030 shares, both fully paid on their acquisition dates. The filing also lists recent sales of common shares by Michael Geffner over the prior three months, including multiple transactions in November 2025 and January 2026.
Immunovant, Inc. reported another quarter of heavy investment in its autoimmune pipeline, led by FcRn inhibitor IMVT-1402, with no product revenue yet. For the three months ended December 31, 2025, net loss was $110.6 million, similar to the prior year.
Quarterly research and development expenses were $98.9 million, reflecting multiple potentially registrational trials across Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP and Sjögren’s disease, plus a proof‑of‑concept study in cutaneous lupus. General and administrative expenses fell to $15.4 million as corporate spending moderated.
The company strengthened its balance sheet with a December 2025 underwritten equity offering of 26.2 million shares at $21.00, generating net proceeds of $543.6 million. Cash and cash equivalents rose to $994.5 million as of December 31, 2025, which management believes can fund announced indications through a potential commercial launch of IMVT-1402 in Graves’ disease.
Immunovant, Inc. reported a fiscal third-quarter 2025 net loss of $110.6 million, or $0.61 per share, driven mainly by research and development spending as it advances its autoimmune pipeline.
For the quarter ended December 31, 2025, R&D expenses were $98.9 million and general and administrative expenses were $15.4 million, with non-GAAP R&D and G&A at $91.1 million and $10.6 million, respectively. Nine-month net loss totaled $357.8 million, or $2.04 per share, with non-GAAP net loss of $312.9 million.
Cash and cash equivalents reached $994.5 million as of December 31, 2025, supported by an underwritten financing that generated approximately $550 million in gross proceeds, which the company believes extends its cash runway to the potential launch of IMVT-1402 in Graves’ disease. Key programs include a fully enrolled potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis, with topline data expected in the second half of 2026, additional potentially registrational IMVT-1402 trials across several autoimmune indications, and Phase 3 batoclimab data in thyroid eye disease expected in the first half of 2026.
Immunovant Chief Technology Officer Jay S. Stout reported selling 1,977 shares of common stock at $26.03 per share. After this sale, he beneficially owns 197,634 shares directly.
The filing explains that this sale was not a discretionary trade. It was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. Of an earlier grant of 100,000 RSUs made on April 17, 2023, 6,250 RSUs vested on January 17, 2026, triggering the tax-related sale.
Immunovant, Inc. reported insider share sales by its Chief Technology Officer, Jay Stout, tied to RSU tax withholding. On January 7, 2026, he sold 1,148 shares of common stock at a weighted average price of $26.51 per share and 55 shares at a weighted average price of $26.92 per share. These sales were executed to cover tax withholding obligations from the vesting and settlement of restricted stock units and were mandated by the company’s “sell to cover” election, rather than being discretionary trades. Following the reported transactions, he directly held 199,611 shares of Immunovant common stock.